Ulasov IV - Search Results

1

The human survivin promoter: a novel transcriptional targeting strategy for treatment of glioma.

Van Houdt WJ, Haviv YS, Lu B, Wang M, Rivera AA, Ulasov IV, Lamfers ML, Rein D, Lesniak MS, Siegal GP, Dirven CM, Curiel DT, Zhu ZB. Van Houdt WJ, et al. Among authors: ulasov iv. J Neurosurg. 2006 Apr;104(4):583-92. doi: 10.3171/jns.2006.104.4.583. J Neurosurg. 2006. PMID: 16619663

2

Genetic replacement of the adenovirus shaft fiber reduces liver tropism in ovarian cancer gene therapy.

Breidenbach M, Rein DT, Wang M, Nettelbeck DM, Hemminki A, Ulasov I, Rivera AR, Everts M, Alvarez RD, Douglas JT, Curiel DT. Breidenbach M, et al. Hum Gene Ther. 2004 May;15(5):509-18. doi: 10.1089/10430340460745829. Hum Gene Ther. 2004. PMID: 15144580

3

A novel ex vivo model system for evaluation of conditionally replicative adenoviruses therapeutic efficacy and toxicity.

Kirby TO, Rivera A, Rein D, Wang M, Ulasov I, Breidenbach M, Kataram M, Contreras JL, Krumdieck C, Yamamoto M, Rots MG, Haisma HJ, Alvarez RD, Mahasreshti PJ, Curiel DT. Kirby TO, et al. Clin Cancer Res. 2004 Dec 15;10(24):8697-703. doi: 10.1158/1078-0432.CCR-04-1166. Clin Cancer Res. 2004. PMID: 15623655

4

Incorporating the survivin promoter in an infectivity enhanced CRAd-analysis of oncolysis and anti-tumor effects in vitro and in vivo.

Zhu ZB, Makhija SK, Lu B, Wang M, Rivera AA, Kim-Park S, Ulasov IV, Zhou F, Alvarez RD, Siegal GP, Curiel DT. Zhu ZB, et al. Among authors: ulasov iv. Int J Oncol. 2005 Jul;27(1):237-46. Int J Oncol. 2005. PMID: 15942665

5

Conditionally replicative adenoviral vectors for malignant glioma.

Sonabend AM, Ulasov IV, Lesniak MS. Sonabend AM, et al. Among authors: ulasov iv. Rev Med Virol. 2006 Mar-Apr;16(2):99-115. doi: 10.1002/rmv.490. Rev Med Virol. 2006. PMID: 16416455 Review.

6

Cross-priming of T cells to intracranial tumor antigens elicits an immune response that fails in the effector phase but can be augmented with local immunotherapy.

Velicu S, Han Y, Ulasov I, Brown IE, El Andaloussi A, Gajewski TF, Lesniak MS. Velicu S, et al. J Neuroimmunol. 2006 May;174(1-2):74-81. doi: 10.1016/j.jneuroim.2006.01.016. Epub 2006 Feb 28. J Neuroimmunol. 2006. PMID: 16504307

7

Oncolytic adenoviral therapy for glioblastoma multiforme.

Sonabend AM, Ulasov IV, Han Y, Lesniak MS. Sonabend AM, et al. Among authors: ulasov iv. Neurosurg Focus. 2006 Apr 15;20(4):E19. Neurosurg Focus. 2006. PMID: 16709024 Review.

8

CD46 represents a target for adenoviral gene therapy of malignant glioma.

Ulasov IV, Tyler MA, Zheng S, Han Y, Lesniak MS. Ulasov IV, et al. Hum Gene Ther. 2006 May;17(5):556-64. doi: 10.1089/hum.2006.17.556. Hum Gene Ther. 2006. PMID: 16716112

9

Enhanced transduction of malignant glioma with a double targeted Ad5/3-RGD fiber-modified adenovirus.

Tyler MA, Ulasov IV, Borovjagin A, Sonabend AM, Khramtsov A, Han Y, Dent P, Fisher PB, Curiel DT, Lesniak MS. Tyler MA, et al. Among authors: ulasov iv. Mol Cancer Ther. 2006 Sep;5(9):2408-16. doi: 10.1158/1535-7163.MCT-06-0187. Mol Cancer Ther. 2006. PMID: 16985075

10

Novel recombinant adenoviral vector that targets the interleukin-13 receptor alpha2 chain permits effective gene transfer to malignant glioma.

Ulasov IV, Tyler MA, Han Y, Glasgow JN, Lesniak MS. Ulasov IV, et al. Hum Gene Ther. 2007 Feb;18(2):118-29. doi: 10.1089/hum.2006.146. Hum Gene Ther. 2007. PMID: 17328684

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

94 results

Search Page

Filters